CEL-101 (C-122)
Insomnia
Phase IIActive
Key Facts
About Celon Pharma
Celon Pharma's mission is to develop and provide innovative therapies for diseases with significant unmet medical needs, primarily in oncology and CNS, while maintaining financial stability through its generic drug operations. Its key achievement is building a fully integrated, GMP/GLP-compliant biopharma platform in Poland, supporting a pipeline of 11 proprietary drug candidates. The company's strategy is defined by this self-funded, end-to-end model, which reduces external dependencies and aims to capture full value from its R&D successes. This approach has established Celon as a unique and strategically important player in the European biopharmaceutical landscape.
View full company profileTherapeutic Areas
Other Insomnia Drugs
| Drug | Company | Phase |
|---|---|---|
| SILENOR | Currax Pharmaceuticals | Approved |
| CLM-IN01 | Closed Loop Medicine | Pre-commercial (UKCA/CE marked) |
| Levroso Long (Diphenhydramine/Melatonin) | NovaMedica | Approved |
| Insomnia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| HS-10384 | Hansoh Pharma | Phase III |
| CGS-2 | Canopy Growth | Phase II |